These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 36823372)

  • 1. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
    Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
    Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
    Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
    Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
    Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.
    Matsumura N; Fujita K; Nishimoto M; Minami T; Tahara H; Yoshimura K; Uemura H
    World J Urol; 2023 Aug; 41(8):2063-2068. PubMed ID: 36040500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management.
    Jazayeri SB; Srivastava A; Shore N
    Curr Opin Urol; 2022 May; 32(3):283-291. PubMed ID: 35552309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
    McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
    Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
    Omrčen T
    Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Mutlu H; Bozcuk H
    J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metastatic castration-resistant prostate cancer-what are rational sequential treatment options?].
    Horak J; Petrausch U; Omlin A
    Urologie; 2023 Dec; 62(12):1295-1301. PubMed ID: 37847397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
    Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
    ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Mokoala K; Reed J; Maseremule L; Ndlovu H; Hlongwa K; Maes A; Morgenstern A; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2210-2218. PubMed ID: 36864360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
    Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
    Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.